Claims for Patent: 10,493,124

Summary for Patent: 10,493,124

Title:	Angiotensin II alone or in combination for the treatment of hypotension
Abstract:	The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
Inventor(s):	Chawla; Lakhmir S. (McLean, VA)
Assignee:	The George Washington University a Congressionally Chartered Not-for-Profit Corporation (Washington, DC)
Application Number:	15/909,617
Patent Claims:	1. A method of treating a human patient suffering from low blood pressure, comprising administering angiotensin II to the patient at an initial rate of about 20 ng/kg/min and titrating the rate down, wherein the angiotensin II is administered at a rate sufficient to achieve and/or maintain a mean arterial pressure (MAP) of about 65 mm Hg or above. 2. The method of claim 1, wherein the rate is titrated down to about 15 ng/kg/min. 3. The method of claim 1, wherein the rate is titrated down to about 10 ng/kg/min. 4. The method of claim 1, wherein the rate is titrated down to about 5 ng/kg/min. 5. The method of claim 1, wherein the rate is titrated down to about 1.25 ng/kg/min. 6. The method of claim 1, wherein the patient has shock, distributive shock, cardiogenic shock, sepsis, or acute kidney injury. 7. The method of claim 6, wherein the angiotensin II consists of the amino acid sequence set forth in SEQ ID NO: 1. 8. The method of claim 7, wherein the angiotensin II is administered intravenously. 9. The method of claim 6, wherein the rate is titrated down to about 15 ng/kg/min. 10. The method of claim 6, wherein the rate is titrated down to about 10 ng/kg/min. 11. The method of claim 6, wherein the rate is titrated down to about 5 ng/kg/min. 12. The method of claim 6, wherein the rate is titrated down to about 1.25 ng/kg/min. 13. The method of claim 1, wherein the angiotensin II consists of the sequence of SEQ ID NO: 1. 14. The method of claim 6, wherein the rate is titrated down to about 0.25 ng/kg/min. 15. The method of claim 1, wherein the rate is titrated down to about 0.25 ng/kg/min. 16. A method of achieving target mean arterial pressure (MAP) of at least about 65 mmHg in a human patient experiencing low blood pressure, comprising administering angiotensin II to the patient at an initial rate of about 20 ng/kg/min and titrating the rate down. 17. The method of claim 16, wherein the rate is titrated down to about 15 ng/kg/min. 18. The method of claim 16, wherein the rate is titrated down to about 10 ng/kg/min. 19. The method of claim 13, wherein the rate is titrated down to about 5 ng/kg/min. 20. The method of claim 13, wherein the rate is titrated down to about 1.25 ng/kg/min. 21. The method of claim 13, wherein the patient has shock, distributive shock, cardiogenic shock, sepsis, or acute kidney injury. 22. The method of claim 21, wherein the angiotensin II consists of the amino acid sequence set forth in SEQ ID NO: 1. 23. The method of claim 22, wherein the angiotensin II is administered intravenously. 24. The method of claim 21, wherein the rate is titrated down to about 15 ng/kg/min. 25. The method of claim 21, wherein the rate is titrated down to about 10 ng/kg/min. 26. The method of claim 21, wherein the rate is titrated down to about 5 ng/kg/min. 27. The method of claim 21, wherein the rate is titrated down to about 1.25 ng/kg/min. 28. The method of claim 21, wherein the rate is titrated down to about 0.25 ng/kg/min. 29. The method of claim 13, wherein the angiotensin II consists of the sequence of SEQ ID NO: 1. 30. The method of claim 16, wherein the rate is titrated down to about 0.25 ng/kg/min.